Conference reports

Potential for easier selection of K65R mutation with tenofovir pressure in subtype C HIV-1 isolates

Categorisation of transmitted HIV drug resistance using the WHO/CDC HIV drug resistance threshold survey method may be useful in resource limited settings

Limitations in online tools to identify HIV-1 subtypes

Resistance implications from PrEP and microbicide studies in macaques

Low-level resistance linked to treatment failure: a role for more sensitive testing for naive patients

Testing for resistance after starting treatment

7th International Workshop on Clinical Pharmacology of HIV Therapy, 20-22 April 2006, Lisbon

Efavirenz levels above recommended upper target in 20% of African patients in Senegal

Lower dose of AZT provides adequate exposure in patients with low body weight

Pharmacokinetics for generic fixed dose combinations for children are comparable to the branded products

Caution against dividing adult FDCs (Triomune) for young children

University of Liverpool audit of paediatric TDM

Age-dependent pharmacokinetics of 3TC in children

Use of small sample drug level monitoring for paediatric PI concentrations

Intracellular and plasma measurements of AZT and 3TC and their metabolites in neonates

Effect of pregnancy on PK of protease inhibitors

Using enzyme inducers to reduce the half-life of nevirapine

Relationship between nevirapine concentrations and virological failure in a clinical setting

Summary of drug interaction studies

Effects of ketoconazole and rifampin on TMC278

Brecanavir interaction study with ritonavir and atazanavir

Fixed-dose formulation of efavirenz/tenofovir/FTC bioequivalent to separate dosing

Saquinavir/r (1000/100mg) levels reduced when taken fasted and should be taken with food

Lack of food effect with Meltrex formulation of lopinavir/r

Food interaction reduces ddI intracellular absorption and supports requirement to take fasted

Conflicting results on how T-20 affects tipranavir

12th Annual Conference of the British HIV Association, 29 March–-1 April 2006, Brighton

HIV in the UK – summaries from BHIVA 12th annual conference

Primary care practice still fails to diagnose HIV patients from high-risk groups or with symptomatic acute infection

Use of HLA-B*5701 genetic testing to reduce abacavir hypersensitivity reactions

Dosing rifabutin and lopinavir/r – sub-optimal rifabutin levels reported in five patients dosed according to current guidelines

Fatal seronegative visceral leishmaniasis in Portuguese patient

Awareness of PEP after sexual exposure (PEPSE)

Final reports from 13th Conference on Retroviruses and Opportunistic Infections (CROI), 5-8 February 2006, Denver

Regimen durability and toxicity in 36-month follow up on ART in Khayelitsha, South Africa

Adults in resource-limited settings are most likely to experience an HIV-associated Illness in the first three months from initiating therapy

Causes of death in adults receiving ARV therapy in Senegal

Rapid scale-up of treatment in Zambia delivered at primary health level

The effect of HIV subtype on disease progression in Rakai, Uganda

Genital tract pharmacokinetics of ten antiretroviral drugs in HIV-positive women

Initiation of ART leads to a rapid decline in cervical and vaginal HIV-1 RNA

Effect of HSV-2 treatment on HIV-1 genital shedding and plasma viral load

Once-daily FTC, ddI, and efavirenz in children and adolescents

Simplified triple NRTI regimen effective in vertically infected children: two years follow-up

Long-term clinical and biological outcomes in children vertically infected with HIV

Prospective follow up of children with lipodystrophy

Tuberculosis in HIV-positive children often missed from incidence data: the influence of HAART on paediatric TB

Nevirapine pharmacokinetics with infant prophylaxis

Prevention of rectal transmission of SIV in macaques using FTC with tenofovir: FTC has independent protective effect even as monotherapy

K65R frequently emerges within 1-6 weeks of tenofovir monotherapy in macaques

A genome armed against HIV

Circumcision: a surprising benefit from an unkind cut

Topical microbicides: the real front line of HIV prevention

Prevention of rectal transmission of SIV in macaques using FTC with tenofovir: FTC has independent protective effect even as monotherapy

Further reports from 13th Conference on Retroviruses and Opportunistic Infections (CROI), 5-8 February 2006, Denver

Pharmacokinetics of antiretrovirals in pregnancy: tenofovir, nelfinavir, lopinavir/r

Risk of central nervous system birth defects associated with ART exposure during pregnancy

No increase in adverse pregnancy outcomes in Thai women receiving nevirapine-containing HAART

ARV treatment following singe dose nevirapine exposure

Association of HIV replication capacity with mother to child transmission

Association between HIV subtype and detection of K103N

Pharmacology and drug interaction studies in adults: summary table from CROI, ICAAC and EACS conferences

Other new antiretrovirals at Denver: the future seems bright

Origins of HIV traced to chimpanzees in Cameroon

HSV-2 suppression reduces HIV and HSV shedding

Post navigation